ROLE OF HYDROXYLATED METABOLITES OF PHENYTOIN IN DOSE-DEPENDENCY

[1]  G. Taylor.  VITAMIN C AND STROKE , 1976, The Lancet.

[2]  G. Levy,et al.  Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity. , 1975, Journal of pharmaceutical sciences.

[3]  S. Stavchansky,et al.  Kinetic and spectral studies of type I and type II compounds with rat hepatic microsomes in the presence of the major metabolite of diphenylhydantoin. , 1975, Drug metabolism and disposition: the biological fate of chemicals.

[4]  A. Richens,et al.  SERUM-PHENYTOIN LEVELS IN MANAGEMENT OF EPILEPSY , 1975, The Lancet.

[5]  S. Stavchansky,et al.  Cross inhibition of drug metabolism by drug metabolites. Increase of zoxazolamine paralysis time by the major metabolite of diphenylhydantoin. , 1974, Research communications in chemical pathology and pharmacology.

[6]  S. Stavchansky,et al.  Increase of hexobarbital sleeping time and inhibition of drug metabolism by the major metabolite of diphenylhydantoin. , 1974, Life sciences.

[7]  A. Glazko.  Diphenylhydantoin metabolism. A prospective review. , 1973, Drug metabolism and disposition: the biological fate of chemicals.

[8]  F. Bochner,et al.  Effect of dosage increments on blood phenytoin concentrations , 1972, Journal of neurology, neurosurgery, and psychiatry.

[9]  J. Ashley,et al.  Inhibition of diphenylhydantoin elimination by its major metabolite. , 1972, Research communications in chemical pathology and pharmacology.

[10]  J. Wagner,et al.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. , 1972, Research communications in chemical pathology and pharmacology.

[11]  A. Glazko,et al.  Colorimetric Assay of 5,5-Diphenylhydantoin (Dilantin 1 ) and 5- (p-Hydroxyphenyl)-5-phenylhydantoin , 1971 .

[12]  J. Strong,et al.  Identification of 5-meta-hydroxyphenyl-5-phenylhydantoin as a metabolite of diphenylhydantoin. , 1970, Biochemical pharmacology.

[13]  K. Arnold,et al.  The rate of decline of diphenylhydantoin in human plasma , 1970, Clinical pharmacology and therapeutics.

[14]  A. Glazko,et al.  Quantitative assay of 5,5-diphenylhydantoin (Dilantin) and 5-(p-hydroxyphenyl)-5-phenylhydantoin by gas-liquid chromatography. , 1970, The Journal of laboratory and clinical medicine.

[15]  F. De Ferrari,et al.  Studies on the passive transfer of amyloidosis by cells. , 1969, The Journal of laboratory and clinical medicine.

[16]  A. Glazko,et al.  Metabolic disposition of diphenylhydantoin in normal human subiects following intravenous administration , 1969, Clinical pharmacology and therapeutics.

[17]  H. Remmer,et al.  [The significance of cumulation and elimination for the determination of Phenytoin (diphenylhydantoin)]. , 1969, Deutsche medizinische Wochenschrift.

[18]  K. Arnold,et al.  Studies on the metabolism of diphenylhydantoin in mice. , 1969, The Journal of pharmacology and experimental therapeutics.

[19]  M. Weiss,et al.  Dose-dependence of drug plasma level decline in dogs. , 1967, The Journal of pharmacology and experimental therapeutics.

[20]  F. Mcdowell,et al.  Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity , 1964, Neurology.